Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells

Cellular Immunology

Volumn 249, Issue 1, 2007, Pages 20-29

  Haque, Azizul ^a,b   Hajiaghamohseni, Laela M ^a,b   Li, Ping ^c   Toomy, Katherine ^c   Blum, Janice S ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antigen presenting cells (APC); CD4+ T cell recognition; Endocytosis and recycling; Fibroblasts; HLA class II; Invariant chain (Ii); Peptide binding; Peptide presentation

Indexed keywords

HLA A11 ANTIGEN; LIGAND;

ANTIGEN PRESENTING CELL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; ENDOCYTOSIS; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; ENDOCYTOSIS; FIBROBLASTS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DR4 ANTIGEN; HUMANS; MICE; MOLECULAR CHAPERONES; PEPTIDES; PROTEIN BINDING;

EID: 38349176856     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2007.10.005     Document Type: Article

References (54)

1. Bryant P.W., Lennon-Dumenil A.M., Fiebiger E., Lagaudriere-Gesbert C., and Ploegh H.L. Proteolysis and antigen presentation by MHC class II molecules. Adv. Immunol. 80 (2002) 71-114
2. Haque A., and Blum J.S. New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases. J. Biol. Regul. Homeost. Agents 19 (2005) 93-104
3. Li P., Gregg J.L., Wang N., Zhou D., O′Donnell P., Blum J.S., and Crotzer V.L. Compartmentalization of class II antigen presentation: contribution of cytoplasmic and endosomal processing. Immunol. Rev. 207 (2005) 206-217
4. Jones E.Y., Fugger L., Strominger J.L., and Siebold C. MHC class II proteins and disease: a structural perspective. Nat. Rev. Immunol. 6 (2006) 271-282
5. Daar A.S., Fuggle S.V., Fabre J.W., Ting A., and Morris P.J. The detailed distribution of MHC class II antigens in normal human organs. Transplant 38 (1984) 293-298
6. Nakagawa T.Y., Brissette W.H., Lira P.D., Griffiths R.J., Petrushova N., Stock J., McNeish J.D., Eastman S.E., Howard E.D., Clarke S.R., Rosloniec E.F., Elliott E.A., and Rudensky A.Y. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 10 (1999) 207-217
7. Dixon A.M., Stanley B.J., Matthews E.E., Dawson J.P., and Engelman D.M. Invariant chain transmembrane domain trimerization: a step in MHC class II assembly. Biochemistry 45 (2006) 5228-5234
8. Stern L.J., Potolicchio I., and Santambrogio L. MHC class II compartment subtypes: structure and function. Curr. Opin. Immunol. 18 (2006) 64-69
9. Maehr R., Kraus M., and Ploegh H.L. Mice deficient in I-chain and MHC class II exhibit a normal mature B2 cell compartment. Eur. J. Immunol. 34 (2004) 2230
10. Busch R., Rinderknecht C.H., Roh S., Lee A.W., Harding J.J., Burster T., Hornell T.M., and Mellins E.D. Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunol. Rev. 207 (2005) 242-260
11. Sant A.J., Chaves F.A., Jenks S.A., Richards K.A., Menges P., Weaver J.M., and Lazarski C.A. The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes. Immunol. Rev. 207 (2005) 261-278
12. Honey K., Forbush K., Jensen P.E., and Rudensky A.Y. Effect of decreasing the affinity of the class II-associated invariant chain peptide on the MHC class II peptide repertoire in the presence or absence of H-2M. J. Immunol. 172 (2004) 4142-4150
13. Pathak S.S., and Blum J.S. Endocytic recycling is required for the presentation of an exogenous peptide via MHC class II molecules. Traffic 1 (2000) 561-569
14. Zhong G., Castellino F., Romagnoli P., and Germain R.N. Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP). J. Exp. Med. 184 (1996) 2061-2066
15. Sinnathamby G., and Eisenlohr L.C. Presentation by recycling MHC class II molecules of an influenza hemagglutinin-derived epitope that is revealed in the early endosome by acidification. J. Immunol. 170 (2003) 3504-3513
16. Pathak S.S., Lich J.D., and Blum J.S. Cutting edge: editing of recycling class II. Peptide complexes by HLA-DM. J. Immunol. 167 (2001) 632-635
17. Ramachandra L., and Harding C.V. Phagosomes acquire nascent and recycling class II MHC molecules but primarily use nascent molecules in phagocytic antigen processing. J. Immunol. 164 (2000) 5103-5112
18. Askew D., Chu R.S., Krieg A.M., and Harding C.V. CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J. Immunol. 165 (2000) 6889-6895
19. Peterson M., and Miller J. Invariant chain influences the immunological recognition of MHC class II molecules. Nature 345 (1990) 172-174
20. Roche P.A., Teletski C.L., Karp D.R., Pinet V., Bakke O., and Long E.O. Stable surface expression of invariant chain prevents peptide presentation by HLA-DR. EMBO J. 11 (1992) 2841-2847
21. Xu M., Lu X., Kallinteris N.L., Wang Y., Wu S., von Hofe E., Gulfo J.V., Humphreys R.E., and Hillman G.G. Immunotherapy of cancer by antisense inhibition of Ii protein, an immunoregulator of antigen selection by MHC class II molecules. Curr. Opin. Mol. Ther. 6 (2004) 160-165
22. Hillman G.G., Kallinteris N.L., Li J., Wang Y., Lu X., Li Y., Wu S., Wright J.L., Slos P., Gulfo J.V., Humphreys R.E., and Xu M. Generating MHC class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC class II inducer and an antisense Ii-RNA construct in tumor cells. Gene Ther. 10 (2003) 1512-1518
23. Tamori Y., Tan X., Nakagawa K., Takai E., Akagi J., Kageshita T., Egami H., and Ogawa M. Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma. Oncol. Rep. 14 (2005) 873-877
24. Datta M.W., Shahsafaei A., Nadler L.M., Freeman G.J., and Dorfman D.M. Expression of MHC class II-associated invariant chain (Ii; CD74) in thymic epithelial neoplasms. Appl. Immunohistochem. Mol. Morphol. 8 (2000) 210-215
25. M.E. Chamuleau, Y. Souwer, S.M. Van Ham, A. Zevenbergen, T.M. Westers, J. Berkhof, C.J. Meijer, A.A. van de Loosdrecht, G.J. Ossenkoppele, Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome, Cancer Res. 64 (2004) 5546-5550 (Erratum in: Cancer Res. 64 (2004) 7181).
26. Koonce C.H., and Bikoff E.K. Dissecting MHC class II export, B cell maturation, and DM stability defects in invariant chain mutant mice. J. Immunol. 173 (2004) 3271-3280
27. Yu M., Xu M., Savas L., and Khan A. Discordant expression of Ii and HLA-DR in thyrocytes: a possible pathogenetic factor in Hashimoto′s thyroiditis. Endocr. Pathol. 9 (1998) 201-208
28. Turvy D.N., and Blum J.S. Detection of biotinylated cell surface receptors and MHC molecules in a capture ELISA: a rapid assay to measure endocytosis. J. Immunol. Methods 212 (1998) 9-18
29. Li P., Haque M.A., and Blum J.S. Role of disulfide bonds in regulating antigen processing and epitope selection. J Immunol. 169 (2002) 2444-2450
30. Hiraiwa A., Yamanaka K., Kwok W.W., Mickelson E.M., Masewicz S., Hansen J.A., Radka S.F., and Nepom G.T. Structural requirements for recognition of the HLA-Dw14 class II epitope: a key HLA determinant associated with rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 87 (1990) 8051
31. Roche P.A., Teletski C.L., Stang E., Bakke O., and Long E.O. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc. Natl. Acad. Sci. USA 90 (1993) 8581-8585
32. Pinet V., Vergelli M., Martin R., Bakke O., and Long E.O. Antigen presentation mediated by recycling of surface HLA-DR molecules. Nature 375 (1995) 603-606
33. Ma C., Whiteley P.E., Cameron P.M., Freed D.C., Pressey A., Chen S.L., Garni-Wagner B., Fang C., Zaller D.M., Wicker L.S., and Blum J.S. Role of APC in the selection of immunodominant T cell epitopes. J. Immunol. 163 (1999) 6413-6423
34. Haque M.A., Hawes J.W., and Blum J.S. Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition. J. Immunol. 166 (2001) 4543-4551
35. Hill C.M., Liu A., Marshall K.W., Mayer J., Jorgensen B., Yuan B., Cubbon R.M., Nichols E.A., Wicker L.S., and Rothbard J.B. Exploration of requirements for peptide binding to HLA DRB1 0101 and DRB1 0401. J. Immunol. 152 (1994) 2890
36. Haque M.A., Li P., Jackson S.K., Zarour H.M., Hawes J.W., Phan U.T., Maric M., Cresswell P., and Blum J.S. Absence of gamma-interferon-inducible lysosomal thiol reductase in melanomas disrupts T cell recognition of select immunodominant epitopes. J. Exp. Med. 195 (2002) 1267-1277
37. Dodi A.I., Brett S., Nordeng T., Sidhu S., Batchelor R.J., Lombardi G., Bakke O., and Lechler R.I. The invariant chain inhibits presentation of endogenous antigens by a human fibroblast cell line. Eur. J. Immunol. 24 (1994) 1632-1639
38. Frauwirth K., and Shastri N. Introducing endogenous antigens into the major histocompatibility complex (MHC) class II presentation pathway. Both Ii mediated inhibition and enhancement of endogenous peptide/MHC class II presentation require the same Ii domains. Immunology 102 (2001) 405-415
39. Frauwirth K., and Shastri N. Mutation of the invariant chain transmembrane region inhibits II degradation, prolongs association with MHC class II, and selectively disrupts antigen presentation. Cell. Immunol. 209 (2001) 97-108
40. Stumptner-Cuvelette P., and Benaroch P. Multiple roles of the invariant chain in MHC class II function. Biochim. Biophys. Acta 1542 (2002) 1-13
41. Germain R.N., and Hendrix L.R. MHC class II structure, occupancy and surface expression determined by post-endoplasmic reticulum antigen binding. Nature 353 (1991) 134
42. Phan U.T., Arunachalam B., and Cresswell P. Gamma-interferon-inducible lysosomal thiol reductase (GILT). Maturation, activity, and mechanism of action. J. Biol. Chem. 275 (2000) 25907-25914
43. Maric M., Arunachalam B., Phan U.T., Dong C., Garrett W.S., Cannon K.S., Alfonso C., Karlsson L., Flavell R.A., and Cresswell P. Defective antigen processing in GILT-free mice. Science 294 (2001) 1361-1365
44. Kukol A., Torres J., and Arkin I.T. A structure for the trimeric MHC class II-associated invariant chain transmembrane domain. J. Mol. Biol. 320 (2002) 1109-1117
45. Karlsson L. DM and DO shape the repertoire of peptide-MHC-class-II complexes. Curr. Opin. Immunol. 17 (2005) 65-70
46. Monji T., McCormack A.L., Yates E., and Pious D. Invariant-cognate peptide exchange restores class II dimer stability in HLA-DM mutants. J. Immunol. 153 (1994) 4468-4477
47. Karlsson L., Peleraux A., Lindstedt R., Liljedahl M., and Peterson P.A. Reconstitution of an operational MHC class II compartment in nonantigen-presenting cells. Science 266 (1994) 1569-1573
48. Ramachandra L., Kovats S., Eastman S., and Rudensky A.Y. Variation in HLA-DM expression influences conversion of MHC class II alpha beta: class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line. J. Immunol. 156 (1996) 2196-2204
49. Lorenz R.G., Blum J.S., and Allen P.M. Constitutive competition by self proteins for antigen presentation can be overcome by receptor-enhanced uptake. J. Immunol. 144 (1990) 1600-1606
50. Dong X., An B., Kierstead L.S., Storkus W.J., Amoscato A.A., and Salter R.D. Modification of the amino terminus of a class II epitope confers resistance to degradation by CD13 on dendritic cells and enhances presentation to T cells. J. Immunol. 164 (2000) 129-135
51. Ilkovitch D., and Ostrand-Rosenberg S. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain. Cancer Immunol. Immunother. 53 (2004) 525-532
52. Qi L., Rojas J.M., and Ostrand-Rosenberg S. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J. Immunol. 165 (2000) 5451-5461
53. J.A. Thompson, M.K. Srivastava, J.J. Bosch, V.K. Clements, B.R. Ksander, S. Ostrand-Rosenberg, The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4(+) T lymphocytes, Cancer Immunol. Immunother. 2007 Aug 28.
54. Nelson C.A., Petzold S.J., and Unanue E.R. Identification of two distinct properties of class II major histocompatibility complex-associated peptides. Proc. Natl. Acad. Sci. USA 90 (1993) 1227-1231